348 related articles for article (PubMed ID: 25856688)
1. Colorectal cancer in a second round after a negative faecal immunochemical test.
Bujanda L; Sarasqueta C; Castells A; Pellisé M; Cubiella J; Gil I; Cosme A; Arana-Arri E; Mar I; Idigoras I; Portillo I;
Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):813-8. PubMed ID: 25856688
[TBL] [Abstract][Full Text] [Related]
2. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening.
van Roon AH; Goede SL; van Ballegooijen M; van Vuuren AJ; Looman CW; Biermann K; Reijerink JC; Mannetje H'; van der Togt AC; Habbema JD; van Leerdam ME; Kuipers EJ
Gut; 2013 Mar; 62(3):409-15. PubMed ID: 22387523
[TBL] [Abstract][Full Text] [Related]
3. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round.
Digby J; Fraser CG; Carey FA; Diament RH; Balsitis M; Steele RJ
J Med Screen; 2017 Jun; 24(2):62-68. PubMed ID: 27370211
[TBL] [Abstract][Full Text] [Related]
4. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
5. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?
Haug U; Grobbee EJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
Gut; 2017 Jul; 66(7):1262-1267. PubMed ID: 27006184
[TBL] [Abstract][Full Text] [Related]
6. Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia.
Kapidzic A; van der Meulen MP; Hol L; van Roon AH; Looman CW; Lansdorp-Vogelaar I; van Ballegooijen M; van Vuuren AJ; Reijerink JC; van Leerdam ME; Kuipers EJ
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1464-71.e4. PubMed ID: 25724706
[TBL] [Abstract][Full Text] [Related]
7. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
[TBL] [Abstract][Full Text] [Related]
8. Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?
Arana-Arri E; Idigoras I; Uranga B; Pérez R; Irurzun A; Gutiérrez-Ibarluzea I; Fraser CG; Portillo I;
BMC Cancer; 2017 Aug; 17(1):577. PubMed ID: 28851318
[TBL] [Abstract][Full Text] [Related]
9. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
10. Comparison with first round findings of faecal haemoglobin concentrations and clinical outcomes in the second round of a biennial faecal immunochemical test based colorectal cancer screening programme.
Clark GR; Fraser CG; Strachan JA; Steele RJ
J Med Screen; 2022 Dec; 29(4):249-254. PubMed ID: 35747907
[TBL] [Abstract][Full Text] [Related]
11. An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme.
Kelley L; Swan N; Hughes DJ
Colorectal Dis; 2013 Sep; 15(9):e512-21. PubMed ID: 23746062
[TBL] [Abstract][Full Text] [Related]
12. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
Van Roosbroeck S; Hoeck S; Van Hal G
Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
[TBL] [Abstract][Full Text] [Related]
13. Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment.
Ribe SG; Botteri E; Løberg M; Randel KR; Kalager M; Nilsen JA; Gulichsen EH; Holme Ø
Int J Cancer; 2023 Apr; 152(7):1414-1424. PubMed ID: 36346118
[TBL] [Abstract][Full Text] [Related]
14. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
15. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
[TBL] [Abstract][Full Text] [Related]
16. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program.
Chiang TH; Chuang SL; Chen SL; Chiu HM; Yen AM; Chiu SY; Fann JC; Chou CK; Lee YC; Wu MS; Chen HH
Gastroenterology; 2014 Dec; 147(6):1317-26. PubMed ID: 25200099
[TBL] [Abstract][Full Text] [Related]
17. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.
Grobbee EJ; Schreuders EH; Hansen BE; Bruno MJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
Gastroenterology; 2017 Nov; 153(5):1251-1259.e2. PubMed ID: 28760383
[TBL] [Abstract][Full Text] [Related]
18. Attendance and yield over three rounds of population-based fecal immunochemical test screening.
Kapidzic A; Grobbee EJ; Hol L; van Roon AH; van Vuuren AJ; Spijker W; Izelaar K; van Ballegooijen M; Kuipers EJ; van Leerdam ME
Am J Gastroenterol; 2014 Aug; 109(8):1257-64. PubMed ID: 24980879
[TBL] [Abstract][Full Text] [Related]
19. Service evaluation of faecal immunochemical testing and anaemia for risk stratification in the 2-week-wait pathway for colorectal cancer.
Chapman C; Bunce J; Oliver S; Ng O; Tangri A; Rogers R; Logan RF; Humes DJ; Banerjea A
BJS Open; 2019 Jun; 3(3):395-402. PubMed ID: 31183456
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
